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of Meningococcal DiseaseMeningococcal disease has always been one of the most
feared infectious diseases among clinicians. It is difﬁcult to
diagnose in the early stages, and it can take a life within hours.
Throughout the world, meningococcal disease rates peak spe-
ciﬁcally among infants and adolescents/young adults, making
this topic particularly pertinent to those treating adolescents and
young adults. The four articles in this supplement to the Journal
of Adolescent Health address the devastating medical, emotional,
and societal impacts of meningococcal disease, track the
changing epidemiology of the disease across the world, and
review the preventive measures aimed at mitigating the effects
of this dreaded disease [1e4].
The article by Dr. Nadel [1] makes it clear that meningococcal
disease is often difﬁcult to recognize in its early stages. It moves
quickly from relatively vague symptoms to sepsis and can have
devastating consequences to the infected individual. Although
the disease is rare, meningococcal disease is associated with a
10% mortality rate with antibiotic treatmentdimproved from a
far higher rate between 70% and 85% before the use of antibiotics.
Approximately 11%e19% of survivors experience signiﬁcant
sequelae. The classic rash that many might mistakenly rely on for
diagnosis is a relatively late symptom; the level of suspicion of
meningococcal disease must always be high, and immediate
treatment with antibiotics should be initiated if the disease is
suspected. The primary targets of treatment include shock and
increased intracranial pressure, the complications of which lead
to ischemia of the skin, limbs, and kidneys, as well as neurologic
sequelae such as cognitive deﬁcits, hearing and visual impair-
ments, and stroke. Thus far, studies of agents that might specif-
ically slow or arrest the effects of the endotoxins that are
responsible for the biological derangements associated with the
disease are producing disappointing results. Dr. Nadel has
includedmultiple algorithms for the treatment of meningococcal
disease that help guide providers with themost recent evidence-
based recommendations. Dr. Nadel paints a frightening picture of
meningococcal disease that exposes the bacteria’s ruthless drive
to destruction. Early detection and intervention are keys to
clinical success when treating disease caused by Neisseria
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http://dx.doi.org/10.1016/j.jadohealth.2016.06.002The epidemiology of meningococcal disease is described in
this up-to-date chronicle of the evolving shifts in serogroup
prevalence throughout the world by Dr. Pelton [2]. The primary
serogroups that cause disease among humans include serogroups
A, B, C, W-135, Y, and X. Each region of theworld has experienced
outbreaks of meningococcal disease; the prevalent serogroups of
N. meningitidis responsible for the outbreaks differ by region. As
each country responds to disease outbreaks by introducing
serogroup-speciﬁc vaccines, the prevalent serogroups in the
region have shifted uniquely based on the vaccine policy for that
region. In the United States, rates of invasive disease have
decreased steadily since the Year 2000, well before the intro-
duction of meningococcal vaccines. Dr. Pelton postulates that the
seasonal peakof invasivemeningococcal disease 2weeks after the
peak inhospitalization for inﬂuenza implies thatmore routineuse
of inﬂuenza vaccination in the United States has impacted the
decline in meningococcal disease rates. Tracking the epidemio-
logic trends of meningococcal disease in the United States is
somewhat challenging due to low disease rates overall. Since the
recommendation for routine use of the quadrivalent conjugate
vaccine addressing serogroups A, C,W, andY in 2005, serogroupB
has become the serogroup most commonly identiﬁed in out-
breaks among university students, and serogroup C is the
serogroup most commonly associated with outbreaks among
men having sex with men. In Europe, the shift from predomi-
nantly serogroup C disease to mostly serogroup B and now an
increasing proportion of serogroup Y disease is likely due to the
widespread use of conjugate vaccines targeting serogroup C. In
Latin American countries, where the use of meningococcal vac-
cines is not widespread, serogroups C andW are gaining ground.
In sub-Saharan Africa, where rates of disease exceed rates seen
elsewhere in the world, disease from serogroup A is decreasing
where vaccines against serogroup A are being used, and the pro-
portionof diseasedue to serogroupWis starting to increase. Cases
due to the relatively rare serogroup X are being seen in Africa,
indicating the need for continued surveillance. As the world
becomesmore interconnectedwithmore efﬁcient forms of travel,
the regional politics of disease and disease prevention through
vaccination may ultimately determine the epidemiology of
disease throughout the world.
The article by Martinón-Torres [3] provides a comprehensive
overview of the costs and burden of meningococcal disease. The
author points to the global burden of disease and the high fatality
rates and seriousmorbidity that result from infection. In addition
to the physical sequelae with which we are most familiar
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points out that meningococcal disease can result in cognitive
impairment, including deﬁcits in memory and executive func-
tioning. He also discusses the increased risk for post-traumatic
stress disorder and other mental health sequelae both in chil-
dren and adolescents who survive meningococcal disease and in
their families. The direct and indirect medical costs of menin-
gococcal disease have been well studied and are summarized in
this article, highlighting the unique issues associated with
developed versus undeveloped countries. Perhaps the most
novel aspects of the article by Martinón-Torres are his emphasis
on the societal and neglected costs of the disease, which are not
typically considered in cost-effectiveness analyses and public
health policy and planning. Some of these neglected burdens
include long-term mental health treatment needs, costs associ-
ated with heightened opiate dependence, long-term effects of
family stress, legal burdens (e.g., the risk of malpractice suits
after misdiagnosis), and the effects of “fear of meningococcal
disease” on medical practice with the potential for increased use
of costly and unnecessary medical tests. These “neglected” bur-
dens are difﬁcult to quantify, and yet they need to be considered
in weighing the beneﬁts of meningococcal vaccination.
The ﬁnal article by Baker [4] provides a useful, detailed
overview of six N. meningitidis serogroups (A, B, C, W, X, and Y)
and focuses on the available vaccines in the United States that
can prevent disease caused by ﬁve of these serogroups. The
quadrivalent conjugate vaccine (MenACWY), which has been
licensed in the United States since 2005, protects against
serogroups A, C, W, and Y. As previously noted, serogroup B, not
covered by the routinely recommended quadrivalent meningo-
coccal vaccine, is now responsible for many of the recent
meningococcus outbreaks in the United States. Two different
serogroup B vaccines have recently been licensed for use in the
United States. Baker does an excellent job of reviewing the
history of meningococcal vaccine development, summarizing
current recommendations, and providing a detailed analysis of
the differences between the two MenB vaccines. In 2005, the
Advisory Committee on Immunization Practices (ACIP) issued a
routine recommendation for MenACWY, which has helped to
establish MenACWY vaccination as part of the routine adolescent
immunization platform [5]. Many states now require MenACWY
vaccination for middle school and/or high school entry [6].
Although ACIP has recommended routine vaccination against
serogroup B vaccines for those at increased risk of disease (e.g.,
those who work with serogroup B bacteria in a laboratory, those
in an area with an outbreak), ACIP has issued a Category B
recommendation (a “permissive” recommendation) for all other
adolescents, which is often interpreted as a weak recommen-
dation [7]. Baker warns that this approach almost certainly leads
to lower vaccination rates. Given the confusion around serogroup
B vaccine recommendations, Baker emphasizes the importanceof increasing knowledge and awareness about serogroup B dis-
ease and the vaccine among health care providers and the public
in general, including adolescents/young adults and their families
and institutions serving large numbers of adolescents and young
adults. It is essential that families understand that the routinely
recommended vaccine against serogroups A, C, W, and Y will not
protect them against all meningococcal serogroups and that an
additional vaccine to protect against serogroup B disease is
available and covered by medical insurance.
As a group, the four articles in this supplement provide
excellent, detailed information about meningococcal disease and
its epidemiology, treatment, and prevention. The supplement is a
valuable resource for health professionals. Readers of these
articles will be extraordinarily well informed about bacterial
meningitis and well equipped to discuss the seriousness of
infection and the importance of prevention through vaccination.Funding Sources
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